Log In Sign up
The largest database of trusted experimental protocols

Architect anti hbs assay

Manufactured by Abbott
Visit Supplier
Sourced in Japan

The Architect anti-HBs assay is a quantitative immunoassay used to detect and measure the presence of hepatitis B surface antibodies (anti-HBs) in human serum or plasma samples. The assay is designed to be used on the Architect i1000SR and i2000SR analyzers.

Automatically generated - may contain errors

Lab products found in correlation

Architect i2000 system, by Abbott (1 mentions) Architect anti hbc assay, by Abbott (1 mentions) Architect hbsag qt assay, by Abbott (1 mentions)

Close spelling variants of this product

ARCHITECT anti-HBs Anti-HBs Architect assay

2 protocols using architect anti hbs assay

1

Antibody Titers in Vaccinated HCWs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibody titers were tested by Abbott Architect anti-HBs assay on the Architect i2000 system (Abbott, Chicago, IL). We also divided all vaccinated HCWs (n=166) into two groups on the basis of completion of their full schedule of vaccination. Group A: those who had completed vaccination more than 5 years ago, and Group B: those who had completed vaccination less than 5 years ago. Another comparison was done between the subjects who had received the booster vaccination less or more than 1 year ago.
Batra V., Goswami A., Dadhich S., Kothari D, & Bhargava N. (2015). Hepatitis B immunization in healthcare workers. Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology, 28(2), 276-280.
+ Open protocol
+ Expand
2

HBV Serology and DNA Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum titers of HBsAg and anti-HBs were measured by chemiluminescence immunoassays using the Architect HBsAg-QT assay and Architect anti-HBs assay (Abbott, Tokyo, Japan), and the lower-limits of detection were 0.05 IU mL−1 and 10 mIU mL−1, respectively. Anti-HBc was measured by chemiluminescence immunoassays using the Architect Anti-HBc assay (Abbott, Japan), with a cutoff value of 121 (link),22 (link). Serum HBV-DNA level was analyzed by TaqMan polymerase chain reaction (PCR) assay (Cobas AmpliPrep/Cobas TaqMan HBV test, v2.0), and the quantitative range was 1.3–8.3 log10 IU mL−1.
Kawagishi N., Suda G., Sakamori R., Matsui T., Onozawa M., Yang Z., Yoshida S., Ohara M., Kimura M., Kubo A., Maehara O., Fu Q., Hosoda S., Tokuchi Y., Suzuki K., Nakai M., Sho T., Morikawa K., Natsuizaka M., Ogawa K., Sakai H., Ohnishi S., Baba M., Takehara T, & Sakamoto N. (2022). Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy. Scientific Reports, 12, 16800.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!